I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis

Objective Little is known about the experiences, values, and needs of people without arthritis who undergo predictive biomarker testing for the development of rheumatoid arthritis (RA). Our study aimed to explore the perspectives of these individuals and describe their information needs. Methods A q...

Full description

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 72; no. 3; pp. 360 - 368
Main Authors Mosor, Erika, Stoffer‐Marx, Michaela, Steiner, Günter, Raza, Karim, Stack, Rebecca J., Simons, Gwenda, Falahee, Marie, Skingle, Diana, Dobrin, Mircia, Schett, Georg, Englbrecht, Matthias, Smolen, Josef S., Kjeken, Ingvild, Hueber, Axel J., Stamm, Tanja A.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2020
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective Little is known about the experiences, values, and needs of people without arthritis who undergo predictive biomarker testing for the development of rheumatoid arthritis (RA). Our study aimed to explore the perspectives of these individuals and describe their information needs. Methods A qualitative, multicenter interview study with a thematic analysis was conducted in Austria, Germany and the UK. Individuals were interviewed who underwent predictive biomarker testing for RA and had a positive test result but no diagnosis of any inflammatory joint disease. Participants included patients with arthralgia and asymptomatic individuals. Information and education needs were developed from the qualitative codes and themes using the Arthritis Educational Needs Assessment Tool as a frame of reference. Results Thematic saturation was reached in 34 individuals (76% female, 24 [71%] with arthralgia, and 10 [29%] asymptomatic individuals). Thirty‐seven codes were summarized into 4 themes: 1) decision‐making around whether to undergo initial predictive testing, 2) willingness to consider further predictive tests, and/or 3) preventive interventions, including medication, and 4) varying reactions after receiving a positive test result. Individuals with arthralgia were more likely to be willing to take preventive action, undergo further testing, and experience psychological distress than asymptomatic individuals. All participants expressed the need for tailored, patient‐understandable information. Conclusion Individuals at risk of RA are currently the subjects of research aimed at developing better predictive strategies and preventive approaches. Their perceptions and needs should be addressed to inform the future development of interventions combined with education.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Drs. Hueber and Stamm contributed equally to this work.
Supported by the European Union’s FP7 Health Programme (project EuroTEAM; FP7‐HEALTH‐F2‐2012‐305549), the Innovative Medicines Initiative (RTCure grant 777357), and the Riksbankens Jubileumsfond (The Swedish Foundation for Humanities and Social Sciences grant M13‐0260:1). Dr. Raza's work was supported by the NIHR Biomedical Research Centre.
Dr. Raza has received consulting fees and/or speaking fees from AbbVie, Bristol‐Myers Squibb, Janssen, Eli Lilly and Company, Pfizer, Roche, Sanofi, and UCB (less than $10,000 each) and research support from AbbVie and Pfizer. Dr. Smolen has received consulting fees and/or speaking fees from AbbVie, Amgen, Astra‐Zeneca, Astro, Bristol‐Myers Squibb, Boehringer‐Ingelheim, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Eli Lilly and Company, MSD, Novartis‐Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB (less than $10,000 each) and research support from AbbVie, Eli Lilly and Company, MSD, Pfizer, and Roche. Dr. Stamm has received speaking fees from AbbVie, Janssen, MSD, Novartis, and Roche (less than $10,000 each) and research support from AbbVie. No other disclosures relevant to this article were reported.
ISSN:2151-464X
2151-4658
2151-4658
DOI:10.1002/acr.23841